Advancing AD Clinical Trials Through Blood-Based Biomarkers & Amyloid PET Webinar
We cannot play this video. The video is embedded from YouTube, your current cookie preferences do not allow the storing of some of the cookies the player will place.
We join the Global Alzheimer's Platform Foundation's (GAP) Chief Commercial Officer, Lammert Albers, hosted a webinar with OurChief Scientific Officer, Robin Wolz, and Fujirebio's Director of Clinical Research and Development, Rachel Radwan, on the importance of collaboration in advancing AD clinical trials with the joint use of Blood-Based Biomarkers and Amyloid PET imaging.
Date: 09/10/2025